Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System [PDF]
Biomedicines, 2022 This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko +9 more
doaj +2 more sources
Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation [PDF]
Frontiers in Cardiovascular Medicine, 2022 BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen +12 more
doaj +2 more sources
Sacubitril-Valsartan in Patients Requiring Hemodialysis [PDF]
JAMA Network OpenKey Points Question Is the use of sacubitril-valsartan associated with reduced risk of all-cause mortality and hospitalization among individuals requiring hemodialysis for heart failure with reduced ejection fraction (HFrEF)? Findings In this comparative
Dustin Le +3 more
openalex +2 more sources
The effect of sacubitril/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study [PDF]
European Heart Journal, 2017 Aims: Progressive aortic stiffening eventually leads to left ventricular (LV) hypertrophy and heart failure if left untreated. Anti-hypertensive agents have been shown to reverse this to some extent. The effects of sacubitril/valsartan (LCZ696), a dual-
Michael Mayr +2 more
exaly +3 more sources
Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. [PDF]
CirculationBACKGROUND: Anthracycline- and trastuzumab-associated cardiotoxicity may lead to cardiac dysfunction and dose reduction or halt of potentially life-saving adjuvant cancer therapy.
Omland T +12 more
europepmc +2 more sources
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial [PDF]
European Journal of Heart Failure, 2016 AimsIn this analysis, we utilized data from PARADIGM-HF to test the hypothesis that participants who exhibited any dose reduction during the trial would have similar benefits from lower doses of sacubitril/valsartan relative to lower doses of enalapril ...
Orly Vardeny +2 more
exaly +3 more sources
Association between sacubitril/valsartan and risk of dementia in patients with heart failure: a nationwide cohort study. [PDF]
Eur Heart J Cardiovasc PharmacotherAims To evaluate the risk of incident dementia associated with sacubitril/valsartan in patients with heart failure (HF) in South Korea. Methods and results We conducted a retrospective cohort study using the National Health Insurance Database in South ...
Jung K +10 more
europepmc +2 more sources
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure [PDF]
Circulation, 2019 Supplemental Digital Content is available in the text. Background: While disease-modifying therapies exist for heart failure (HF) with reduced left ventricular ejection fraction (LVEF), few options are available for patients in the higher range of LVEF (>
Scott D. Solomon +24 more
openalex +2 more sources
Efficacy and safety of sacubitril/valsartan in end-stage renal disease patients with heart failure: a review. [PDF]
Ann MedPurpose End-stage renal disease (ESRD) is associated with a heavy global public health burden and an increased risk of cardiovascular diseases. Sacubitril/valsartan has been shown to improve cardiovascular outcomes in patients with heart failure and ...
Li P, Li Y, Zhang L.
europepmc +2 more sources